HER2 testing and targeted therapy are well established in the management of breast cancer. Now, a study by Chiu and colleagues reports that HER3 status is also an important prognostic marker of ...

HER3 is expressed in more than 80% of EGFR-mutant ... Meanwhile, Daiichi Sankyo and AZ – its partner for approved HER2-targeting ADC Enhertu (trastuzumab deruxtecan) and investigational TROP2 ...

The drug inhibits HER2 dimer formation with other HER family members, such as HER3 and HER1. Genentech is currently studying a combination of both HER2 inhibitors in breast cancer. “With this ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

HER3 is expressed in more than 80% of EGFR-mutant ... Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third ...